Group 1 - The core point of the announcement is that Beijing Kain Technology Co., Ltd. has signed a supplementary agreement regarding the technology transfer contract with Hangzhou Xianweida Biotechnology Co., Ltd. for GLP-1 related drug technology, clarifying future revenue arrangements from this collaboration [1][2] - The original technology transfer contract was signed in May 2019, allowing Kain Technology to receive a share of future floating revenues from the technology results generated by Xianweida [1][2] - The supplementary agreement specifies that Kain Technology will receive a revenue share of 5% for products developed using recombinant expression technology and 2.5% for those using chemical synthesis [3][2] Group 2 - The signing of the supplementary agreement aims to further clarify revenue sharing arrangements based on different production processes for products derived from the original contract [3] - The agreement is expected to have no significant adverse impact on the company's financial status and aligns with its long-term strategic goals [3][2] - The future revenues from the technology transfer contract and supplementary agreement depend on the actual progress of product development, commercialization, and may be influenced by various external factors [4]